Core Viewpoint - The Hong Kong stock market continues to show weakness, particularly in the innovative drug sector, which is experiencing a significant influx of capital despite recent declines in stock prices [1][3][5]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) fell by 1.62%, with a trading volume exceeding 1.65 billion yuan, while it received a net inflow of nearly 16 million yuan during the day [1]. - Over the past ten days, the ETF has attracted over 1.88 billion yuan, bringing its total size to over 8.9 billion yuan, leading its peers in the same category [1]. - Most constituent stocks of the ETF showed negative performance, with notable declines including Rongchang Bio down over 6%, and others like Innovent Biologics and WuXi Biologics down over 4% [3]. Group 2: Policy Support and Investment Trends - Guojin Securities reports that the recent strong performance of innovative drugs is due to multiple factors, including increased policy support for innovative drug development and the encouragement of commercial health insurance to invest in innovative drugs [4][5]. - The National Healthcare Security Administration and the National Health Commission have issued a notice to support high-quality development of innovative drugs, indicating a significant increase in policy support [5]. - The focus on innovative drug business development (BD) remains a key investment theme, especially in light of the global trend of multinational corporations seeking potential blockbuster drugs [7]. Group 3: Investment Opportunities - The potential collaboration between AstraZeneca and Summit Therapeutics, valued at up to 15 billion USD for the AK112 drug, has sparked renewed interest in PD-1/VEGF dual antibodies, highlighting investment opportunities in this area [6]. - The innovative drug sector is expected to benefit from the recent policy measures that will direct healthcare resources towards innovative drugs, accelerating commercialization and profitability for innovative drug companies [7]. - The ETF's underlying assets are entirely focused on the innovative drug industry, with the top ten holdings accounting for nearly 72% of its weight, indicating a strong emphasis on leading companies in this sector [10][11].

Investment Rating - The report maintains a strong confidence in the pharmaceutical sector, particularly in innovative drugs, predicting a reversal trend in 2025 [4] Core Viewpoints - The innovative drug sector is experiencing strong performance driven by multiple factors, including the completion of quarterly portfolio adjustments, increased policy support from the National Healthcare Security Administration (NHSA) and the National Health Commission, and significant collaborations in the industry [1][11] - The NHSA and the National Health Commission have jointly released measures to support the high-quality development of innovative drugs, which will accelerate the commercialization of domestic innovative products and create a positive cycle of profitability and strong R&D investment [20][21] - The report highlights the potential of dual/multi-target antibodies in cancer treatment and innovative drugs addressing unmet clinical needs in chronic diseases as key investment opportunities [1][4] Summary by Sections Innovative Drugs - The innovative drug sector remains the main investment line, with a focus on dual/multi-target antibodies for various cancers and chronic diseases [1][11] - AstraZeneca is in talks for a collaboration worth up to $15 billion for the AK112 drug, which has catalyzed strong performance in related stocks [1] Pharmaceutical Sector - The NHSA's new measures will direct more healthcare resources towards innovative drugs, enhancing their commercialization and profitability [20][21] - The report notes that since 2018, 149 innovative drugs have been included in the healthcare insurance directory, significantly increasing the proportion of new drugs covered [22] Biologics - Changchun High-tech's new drug, Vuxin Qibai monoclonal antibody, has been approved for treating acute gout arthritis, marking a significant advancement in biologics [29][34] - The drug shows rapid onset of action and a substantial reduction in recurrence risk, highlighting its clinical significance [33][34] Traditional Chinese Medicine - Lingrui Pharmaceutical's new indication for its nasal spray is expected to boost sales, with ongoing efforts to expand hospital coverage and OTC sales [38][41] Medical Devices - The report emphasizes policy support for high-end medical devices, predicting accelerated commercialization in various segments such as medical robots and AI [3][4] Medical Services - Recent policies to enhance maternity benefits are expected to stimulate demand in related services [3][4]